Patents by Inventor Jane L. Grogan

Jane L. Grogan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TIGIT ANTIBODIES AND METHODS OF USE
    Publication number: 20240117037
    Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.
    Type: Application
    Filed: June 30, 2023
    Publication date: April 11, 2024
    Inventors: Jane L. GROGAN, Robert J. JOHNSTON, Yan WU, Wei-Ching LIANG, Patrick LUPARDUS, Mahesh YADAV, Dhaya SESHASAYEE, Meredith HAZEN
  • METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS
    Publication number: 20240082396
    Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.
    Type: Application
    Filed: October 13, 2023
    Publication date: March 14, 2024
    Inventor: Jane L. GROGAN
  • ANTI-TIGIT ANTIBODIES AND METHODS OF USE
    Publication number: 20230279102
    Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.
    Type: Application
    Filed: December 7, 2022
    Publication date: September 7, 2023
    Inventors: Jane L. GROGAN, Robert J. JOHNSTON, Yan WU, Wei-Ching LIANG, Patrick LUPARDUS, Mahesh YADAV, Dhaya SESHASAYEE, Meredith HAZEN
  • METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS
    Publication number: 20230226180
    Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.
    Type: Application
    Filed: January 13, 2023
    Publication date: July 20, 2023
    Inventor: Jane L. GROGAN
  • METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS
    Publication number: 20220331426
    Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.
    Type: Application
    Filed: June 1, 2022
    Publication date: October 20, 2022
    Applicant: Genentech, Inc.
    Inventor: Jane L. GROGAN
  • ANTI-TIGIT ANTIBODIES AND METHODS OF USE
    Publication number: 20220064286
    Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.
    Type: Application
    Filed: November 15, 2021
    Publication date: March 3, 2022
    Inventors: Jane L. GROGAN, Robert J. JOHNSTON, Yan WU, Wei-Ching LIANG, Patrick LUPARDUS, Mahesh YADAV, Dhaya SESHASAYEE, Meredith HAZEN
  • ANTI-TIGIT ANTIBODIES AND METHODS OF USE
    Publication number: 20210253693
    Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.
    Type: Application
    Filed: April 29, 2021
    Publication date: August 19, 2021
    Inventors: Jane L. GROGAN, Robert J. JOHNSTON, Yan WU, Wei-Ching LIANG, Patrick LUPARDUS, Mahesh YADAV, Dhaya SESHASAYEE, Meredith HAZEN
  • METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS
    Publication number: 20210113693
    Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 22, 2021
    Inventor: Jane L. GROGAN
  • ANTI-TIGIT ANTIBODIES AND METHODS OF USE
    Publication number: 20210032328
    Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.
    Type: Application
    Filed: October 6, 2020
    Publication date: February 4, 2021
    Inventors: Jane L. GROGAN, Robert J. JOHNSTON, Yan WU, Wei-Ching LIANG, Patrick LUPARDUS, Mahesh YADAV, Dhaya SESHASAYEE, Meredith HAZEN
  • METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS
    Publication number: 20200289647
    Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.
    Type: Application
    Filed: April 8, 2020
    Publication date: September 17, 2020
    Inventor: Jane L. GROGAN
  • COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND TIGIT INHIBITORS
    Publication number: 20190194339
    Abstract: The present invention describes combination therapy comprising an OX40 binding agonist and an agent that decreases or inhibits TIGIT expression and/or TIGIT activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired, such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: June 26, 2018
    Publication date: June 27, 2019
    Inventors: Jeong M. Kim, Jane L. Grogan
  • COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND TIGIT INHIBITORS
    Publication number: 20190169304
    Abstract: The present invention describes combination therapy comprising an OX40 binding agonist and an agent that decreases or inhibits TIGIT expression and/or TIGIT activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired, such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 6, 2019
    Inventors: Jeong M. Kim, Jane L. Grogan
  • ANTI-TIGIT ANTIBODIES AND METHODS OF USE
    Publication number: 20190119376
    Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.
    Type: Application
    Filed: May 31, 2018
    Publication date: April 25, 2019
    Inventors: Jane L. GROGAN, Robert J. JOHNSTON, Yan WU, Wei-Ching LIANG, Patrick LUPARDUS, Mahesh YADAV, Dhaya SESHASAYEE, Meredith HAZEN
  • Anti-TIGIT antibodies and methods of use
    Patent number: 10047158
    Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: August 14, 2018
    Assignee: Genentech, Inc.
    Inventors: Jane L. Grogan, Robert J. Johnston, Yan Wu, Wei-Ching Liang, Patrick Lupardus, Mahesh Yadav, Dhaya Seshasayee, Meredith Hazen
  • Anti-tigit antibodies and methods of use
    Patent number: 10017572
    Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: July 10, 2018
    Assignee: Genentech, Inc.
    Inventors: Jane L. Grogan, Robert J. Johnston, Yan Wu, Wei-Ching Liang, Patrick Lupardus, Mahesh Yadav, Dhaya Seshasayee, Meredith Hazen
  • ANTI-TIGIT ANTIBODIES AND METHODS OF USE
    Publication number: 20180186875
    Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.
    Type: Application
    Filed: February 13, 2018
    Publication date: July 5, 2018
    Inventors: Jane L. GROGAN, Robert J. JOHNSTON, Yan WU, Wei-Ching LIANG, Patrick LUPARDUS, Mahesh YADAV, Dhaya SESHASAYEE, Meredith HAZEN
  • METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS
    Publication number: 20180169239
    Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.
    Type: Application
    Filed: February 7, 2018
    Publication date: June 21, 2018
    Inventor: Jane L. GROGAN
  • METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS
    Publication number: 20170143825
    Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.
    Type: Application
    Filed: January 10, 2017
    Publication date: May 25, 2017
    Inventor: Jane L. GROGAN
  • ANTI-TIGIT ANTIBODIES AND METHODS OF USE
    Publication number: 20170088613
    Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.
    Type: Application
    Filed: September 23, 2016
    Publication date: March 30, 2017
    Inventors: Jane L. GROGAN, Robert J. JOHNSTON, Yan WU, Wei-Ching LIANG, Patrick LUPARDUS, Mahesh YADAV, Dhaya SESHASAYEE, Meredith HAZEN
  • COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND TIGIT INHIBITORS
    Publication number: 20160152720
    Abstract: The present invention describes combination therapy comprising an OX40 binding agonist and an agent that decreases or inhibits TIGIT expression and/or TIGIT activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired, such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Application
    Filed: October 29, 2015
    Publication date: June 2, 2016
    Inventors: Jeong M. KIM, Jane L. GROGAN